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T cell chimeric antigen receptor (CAR) technology has allowed for the introduction
of a high degree of tumor selectivity into adoptive cell transfer therapies. Evolution
of this technology has produced a robust antitumor immunotherapeutic strategy that
has resulted in dramatic outcomes in liquid cancers. CAR-expressing T-cells (CARTs)
targeting CD19 and CD20 have been successfully used in the treatment of hematologic
malignancies, producing sustained tumor regressions in a majority of treated patients.
These encouraging results have led to a historic and unprecedented FDA approval of
CTL019, Novartis’ CAR T-cell therapy for the treatment of children and young adults
with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). However, the
translation of this technology to solid tumors, like malignant gliomas (MG), has thus far
been unsuccessful. This review provides a timely analysis of the factors leading to the
success of CART immunotherapy in the setting of hematologic malignancies, barriers
limiting its success in the treatment of solid tumors, and approaches to overcome these
challenges and allow the application of CART immunotherapy as a treatment modality
for refractory tumors, like malignant gliomas, that are in desperate need of effective
therapies.
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INTRODUCTION
The field of oncology has been revolutionized by the emergence of cellular immunotherapies that
harness and augment the natural capacity of the immune system to fight cancer. As this ability is
often impaired in tumor-bearing patients, one promising approach is to directly bolster deficient
endogenous immune responses with adoptive T-cell therapy, which involves the passive infusion
of activated, ex vivo expanded autologous lymphocytes that have been activated against tumor-
associated antigens (TAAs) (1). These final effectors of the adaptive immune system selectively
identify and destroy malignant cells, leaving healthy tissues unharmed. Furthermore, the natural
development of memory cells allows for the establishment of long-lasting antitumor immunity and
protection from tumor recurrence. However, as the majority of TAAs are poorly immunogenic,
it is often difficult to culture a population of lymphocytes whose T-cell receptors (TCRs) have
adequate avidity to exert sufficient cytotoxicity to produce lasting tumor eradication (2). This
barrier can be overcome with the introduction of engineered surface receptors that have enhanced
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avidity and affinity for a given TAA. These chimeric antigen
receptors (CARs) are comprised of an antibody-derived antigen
recognition domain joined to an internal T-cell signaling domain
and recognize their antigen targets through a mechanism distinct
from classical TCRs (3). In addition to endowing T-cells with
antibody-like specificity, these MHC-unrestricted receptors are
compatible with patients of all HLA subtypes and can be used to
identify tumor cells that have downregulated antigen processing
and presentation functions as an adaptation to evade T-cell-
mediated destruction (4). In this highly personalized form of
immunotherapy, CAR-expressing T-cells (CARTs) combine the
strengths of cellular and humoral immunity to equip a patient’s
immune system with an army of uniquely tumor-specific effector
cells that have been functionally enhanced to have superior
cytotoxicity, persistence, and antigen recognition capabilities in
the face of tumor-induced immunosuppressive influences (5, 6).
Adoptive T-cell therapy with CAR-expressing T-cells has
emerged as one of the most promising cancer immunotherapy
modalities, demonstrating remarkable antitumor efficacy,
particularly in the treatment of hematologic cancers. CARTs
targeting CD19, a ubiquitously expressed B-cell surface antigen,
have induced durable, sustained antitumor immune responses
in patients with acute lymphoblastic leukemia (ALL), chronic
lymphocytic leukemia, multiple myeloma, and treatment-
refractory diffuse large B-cell lymphoma (DLBCL) (7–13). These
encouraging results have prompted the recent, first of its kind,
FDA approval of CTL019, Novartis’ CAR T-cell therapy for
children and young adults with relapsed or refractory B-cell
ALL (14).
Inspired by this success in liquid tumors, there has been
great interest in expanding the use of CART technology to the
treatment of solid tumors like glioblastoma (GBM), a highly
aggressive form of primary brain cancer for which there is no
known cure (15). Supporting the exploration of T-cell-based
therapies in solid tumors is the strong positive correlation
between the degree of intratumoral infiltration with antigen-
specific cytotoxic T-cells (CTLs) and overall patient survival
(16, 17). Given the importance of the delicate balance between
host and tumor immune responses on the ultimate course
of disease, these patients are likely to benefit from highly
sophisticated treatments like CART immunotherapy that can
both strengthen antitumor immunity and overcome tumor-
induced immunosuppressive influences, to tip the balance
toward tumor cell death, Figure 1.
CART immunotherapy may also have superior therapeutic
efficacy in the treatment of solid cancers that are otherwise
poorly accessible to standard therapies, such as malignant
gliomas (MG). Nestled within the brain parenchyma, these
tumors are particularly dangerous to remove with relatively
nonspecific therapies like surgery and radiation due to the risk
of damaging surrounding eloquent brain tissue. Furthermore, the
highly infiltrative growth pattern of aggressive tumors like GBM
makes a complete, curative resection impossible. Intracranial
tumors are further isolated from the systemic circulation by the
presence of a blood brain barrier, which restricts the passage
of most chemotherapeutic agents, preventing their therapeutic
accumulation within tumor sites and increasing the risk of
systemic toxicity (18). With a known ability to cross the blood
brain barrier, activated T-cell-based therapies have potential
to overcome these challenges to safely and effectively reach
surgically inaccessible malignant cells. A cellular-based approach
using functionally enhanced, antigen-specific CTLs, which have
cytotoxic functions restricted to antigen-expressing tumor cells,
represents a particularly promising treatment strategy for these
intracranial tumors (19).
Unfortunately, in stark contrast to the success observed
with hematologic malignancies, CARTs have exhibited limited
efficacy in the treatment of solid tumors. However, this form
of immunotherapy is still in its infancy and there have
been many exciting advances in recent years with significant
potential to revolutionize CART application to solid tumors.
In this review, we highlight the landmark discoveries that have
led to the success of CART immunotherapy in hematologic
malignancies, identify barriers to its application in solid
tumors, and propose research avenues for novel approaches
to overcome these barriers and allow successful application
of CART immunotherapy to treatment-resistant solid tumors,
with a special emphasis on the primary malignant brain cancer,
GBM.
CHIMERIC ANTIGEN RECEPTORS
CARs are synthetic antigen receptors that can be introduced
into an immune cell to retarget its cytotoxicity toward a
specific tumor antigen with a greater degree of specificity.
In contrast to traditional TCRs, which identify intracellularly
derived peptide antigens presented by MHC molecules, CARs
directly identify antigens expressed on the surface of tumor
cells therefore are not restricted by patient HLA subtype and
can recognize a variety of antigen structures including proteins,
carbohydrates, and glycolipids (20). These membrane-bound
fusion proteins couple a high avidity extracellular antigen
recognition moiety derived from the single-chain variable
fragment of a monoclonal antibody with a modified TCR
intracellular signaling domain Figure 2 (3). Originally derived
from the CD3ζ chain of the traditional TCR (21), CAR
endodomains have undergone generational changes to include
one or more costimulatory domains, most commonly CD28
and 41BB, to enhance the persistence and cytotoxicity of CAR-
expressing cells (22, 23).
Following receptor design, a gene encoding the CAR construct
is transfected into the genome of T-cell isolates using gene-
therapy viral vectors, and the resulting CAR T-cells are expanded
ex vivo and re-infused into the patient. Classical CART therapy
is restricted to the use of autologous leukocytes due to the
presence of self-identification molecules on the surface of
T-cells. However, treatment-related lymphopenia may preclude
the ability to isolate sufficient peripheral blood leukocytes
for treatment. These patients may benefit from donor cell
based therapies that use universal CAR T-cells that have been
genetically modified to completely lack endogenous expression
of self-identifying molecules like the TCR and HLA class I
molecules (24, 25).
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FIGURE 1 | Immune-mediated interactions in solid tumors and rationale for CART immunotherapy. (A) Release of cell debris and tumor antigens from malignant cells
activates a cascade of host antitumor immune responses, initiated by innate immune cells that release pro-inflammatory cytokines and contribute to tumor cell
destruction. Among these cells are dendritic cells, which capture tumor antigens, mature in response to the pro-inflammatory cytokines in the environment, and travel
to lymphoid tissues to stimulate T-cell proliferation and activation of antigen-specific adaptive immune responses leading to tumor death. (B). Tumors often develop
adaptations to evade detection and destruction by the host immune system. Through the recruitment of suppressive leukocytes and elaboration of
immunosuppressive cytokines, tumors inhibit the function of infiltrating immune cells, including dendritic cells. Incompletely matured DCs are unable to effectively
activate naïve T cells, instead inducing T-cell anergy, apoptosis, or tolerance to tumor-associated antigens. Downregulation of antigen-presenting machinery and the
development of antigen-loss variants enable tumor cells to escape detection by infiltrating immune cells. (C) CAR T-cells, which recognize antigens via a mechanism
distinct from TCR stimulation, bypass the need for DC antigen presentation and are unaffected by MHC downregulation. CAR structure and culture conditions can
also be optimized to create CART populations with superior cytotoxicity and resistance to tumor-induced suppressive influences.
CART AND HEMATOLOGICAL
MALIGNANCIES
Since the first design of chimeric T-cell receptors in 1989, CAR
technology and the field of CART immunotherapy have advanced
immensely, with several key landmark achievements that have
propelled this therapeutic modality to the forefront of cancer
treatment, Figure 3 (3). Evaluated in a variety of tumor types,
CART immunotherapy has produced particularly successful
clinical responses in the treatment of hematologic malignancies.
CAR T-cells targeting B-cell surface antigens, particularly
CD19, have demonstrated a marked ability to eradicate liquid
tumors (27, 28). Upon introduction into human clinical trials,
CART immunotherapy induced sustained tumor regression in a
majority of treated patients (7–13). This success prompted the
recent FDA approval of CTL019, Novartis’s CAR T-cell therapy
for the treatment of children and young adults with relapsed
or refractory B-cell ALL, bringing CART immunotherapy to the
front lines of standard cancer treatment (14).
Reflecting on the success of CART immunotherapy in
hematologic cancers, tumors of B-cell origin possess several
qualities that have provided for this exceptional antitumor
efficacy. Primarily, this can be attributed to the virtually
ideal properties of CD19 as an antigen target. Ideal antigens
for CAR generation are tumor exclusive, expressed by all
malignant cells, and have a function crucial to tumor growth
and survival. Together, these qualities maximize tumoricidal
capacity, prevent immune evasion, and reduce the risk of
toxicity stemming from CART destruction of antigen-expressing
healthy cells. Uniformly expressed by malignant cells of
B-cell cancers CD19 is lineage-restricted B-cell surface marker
that is not present on other tissues of the body (29).
Although non-cancerous immune cells also express CD19,
transient inadvertent destruction of these populations during
treatment does not result in therapy-limiting toxicity (30).
Additionally, malignant cells of hematologic cancers typically
reside in locations of routine T-cell migration (peripheral
blood, lymph nodes, and bone marrow), making them readily
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FIGURE 2 | CAR structure. CARs are comprised of an antigen-recognition ectodomain derived from the single-chain variable fragment (scFv) of a monoclonal
antibody connected by a flexible hinge and transmembrane segment to an intracellular endodomain. Originally derived from the CD3ζ domain of the classical TCR in
(A) first generation CARs, this intracellular signaling component may contain (B) one (second generation) or (C) two (third generation) additional costimulatory domains
that enhance the proliferation, persistence, and efficacy of adoptively transferred cells.
FIGURE 3 | Development of CART immunotherapy. Following development of the first chimeric T-cell receptor in 1989, early preclinical studies of the first CARTs
demonstrated the ability to selectively identify and destroy antigen-expressing tumor cells (5, 6). However, upon adoptive transfer into live patients, T-cells expressing
these first-generation CARs displayed limited persistence and were often rendered anergic due to the absence of costimulatory signals within the tumor
microenvironment (TME) (26). With the introduction of costimulatory domains to provide these necessary activating signals, CART immunotherapy experienced a
dramatic improvement in therapeutic efficacy (22). Optimization of CAR structure and ex vivo culture conditions to improve CART persistence, cytotoxicity, and
resistance to tumor-induced immunosuppression remains an area of continued research. Evaluated in a variety of tumor types, CART immunotherapy has been
markedly successful in the eradication of liquid tumors, culminating in the FDA approval of CART immunotherapy for the treatment of relapsed or refractory B-cell ALL
in 2017.
accessible to systemically delivered CAR T-cells. A relatively
disseminated distribution also precludes tumor isolation by
physical barriers such as a dense fibrous stroma and the
development of a highly immunosuppressive local tumor
microenvironment (TME). The combination of these factors has
allowed for the rapid, efficient, and uninhibited destruction of
CD19-positive malignant cells leading to regression of B-cell
cancers.
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CART AND SOLID MALIGNANCIES
CARs have also been developed against a variety of solid tumor
surface antigens including mesothelin (31), carcinoembryonic
antigen (CEA) (32), disialoganglioside (GD2) (33), interleukin-
13 receptor α2 (IL-13Rα2) (34), mucin-1 (MUC1) (35, 36),
ephrin type-A receptor 2 (EphA2), (37), human epidermal
growth factor receptor 2 (HER2) (38) and other growth factor
receptors. Currently there are several ongoing clinical trials
assessing the safety and efficacy of CART immunotherapy in
various solid malignancies (Table 1).
With respect to GBM, much of the current CAR development
is focused on the following antigen targets: EGFRvIII, IL-13Rα2,
and HER2. EGFRvIII is a mutated form of the epidermal growth
factor receptor (EGFR), resulting from a tumor-specific in-
frame deletion creating a constitutively active surface receptor
protein. Present in approximately 30% of GBMs, this mutant
receptor enhances glioma cell proliferation, angiogenesis, and
invasiveness (39) and is independently associated with a poor
prognosis (40). Preclinical studies have established the ability of
T-cells targeting this unique, tumor-specific epitope to proliferate
and release cytokines in response to stimulation with the
mutant EGFRvIII antigen, but not wild-type EGFR (41). In
preclinical studies, EGFRvIII-targeting CARTs effectively traffic
to tumor sites and suppress the growth of glioma xenografts
in murine models (42). In human clinical trials, preliminary
reports from a phase I study in 10 patients with recurrent GBM
established the safety and feasibility of EGFRvIII-targeting CART
immunotherapy. Adoptively transferred cells were shown to
proliferate within the peripheral blood and traffic to intracranial
tumor sites, exerting antitumor effects without any evidence
of cross-toxicity with wild-type EGFR. Interestingly, analysis of
pre- and post-treatment tumor samples revealed post-treatment
decreases in antigen expression and an increased presence of
inhibitory immune checkpoint molecules and regulatory T-cell
infiltrates, indicative of evasive tumor responses. The median
overall survival was approximately 8 months, with one patient
experiencing residual stable disease at 18 months (43). Clinical
trials are currently ongoing specifically to assess efficacy.
Another encouraging target for patients with GBM is
interleukin-13 receptor alpha-2 (IL-13Rα2). Not expressed by
healthy tissues, IL-13Rα2 is overexpressed in nearly all GBM
tumors (44). IL-13Rα2-targeting CARTs have been shown to
selectively target and kill IL-13Rα2-positive tumor cells in vitro
and in vivo, producing regression of xenograft glioma tumors in a
murine model (34). Based on this success, several human clinical
trials were initiated with IL-13Rα2-targeting CARTs. Transient
anti-glioma responses, without significant associated toxicities,
were observed in a subset of treated patients (45, 46).
Human epidermal growth factor receptor 2 (HER2) is a
transmembrane tyrosine kinase receptor expressed on a variety
of healthy tissues. Overexpressed inmany solid tumors, including
approximately 15% of GBM tumors, HER2 has been identified as
an independent negative prognostic indicator for GBM patient
survival (47). In a recent phase I dose-escalation study of HER2-
specific CAR-modified virus-specific T-cells for the treatment
of progressive HER2-positive glioblastoma, therapy was well
tolerated without any dose-limiting toxicities. Median overall
survival was 11.1 months from the time of first infusion, and 24.5
months from initial diagnosis (48).
CARTs targeting these and other TAAs have shown significant
antitumor activity in in vitro and in vivo preclinical studies
(Table 2), and many of these therapies have reached the stage
of human clinical trials for patients with GBM (Table 3). Across
all solid tumors, one of the most promising studies has occurred
in the treatment of neuroblastoma with GD2-targeting CARTs,
where complete remission was achieved in 3 of 11 treated patients
(57). However, in stark contrast to the efficacy in hematologic
malignancies, no CAR T-cell therapy has been shown to induce
consistent, lasting regression of solid tumor in human patients.
CHALLENGES FACING CART THERAPY IN
SOLID TUMORS
For CAR T-cells to effectively eradicate solid tumors in human
patients, they must be able to migrate to and infiltrate tumor
tissues, proliferate and persist long enough to exert therapeutic
effects, and identify and destroy only antigen-expressing cells
within the TME. However, the ability for CART cells to these
goals has thus far been hindered by a variety of factors unique
to solid tumors, Figure 4.
Selection of Tumor-Associated Antigens
Perhaps the greatest challenge facing the successful application
of CART technology to solid tumors in human patients is the
selection of acceptable antigen targets. Solid tumors develop
from the accumulation of a variety different mutations that
promote unchecked cellular growth and proliferation, some of
which result in the creation of tumor-exclusive epitopes that
can be used to selectively identify malignant cells. However,
rather than occurring linearly with the progression of a single
homogenous line of cells expressing all accumulated mutations,
tumorigenesis transpires through the simultaneous evolution
and adaptation of individual malignant cells. As a result, solid
tumors are comprised of highly molecularly heterogeneous
subpopulations expressing a diverse, overlapping profile of
unique TAAs. As a result, the current pool of potential antigens
for CAR development in solid tumors is comprised of suboptimal
targets that either lack uniformity of expression or tumor
exclusivity, introducing additional concerns for efficacy and
safety. In addition to precluding the identification of commonly
and uniformly expressed targets for CAR development, this
naturally-derived molecular heterogeneity both between patients
and within individual tumors is difficult to reproduce in the
human cell line-derived relatively homogeneous tumors utilized
in preclinical experiments, limiting the ability of these studies to
truly approximate human disease and predict patient responses
to treatment (58).
To prevent inadvertent destruction of healthy tissues, CARTs
are ideally designed to target antigens exclusively expressed
by malignant cells. However, the vast majority of mutations
producing novel epitopes in solid tumors occur through the
processing of intracellular proteins, which are presented in
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TABLE 1 | List of CART immunotherapy clinical trials in solid tumors (except gliomas).
Malignancy Phase N Name of Trial Therapeutic
Compounds
Clinical Trial
Identifier
Status
GPC3 Positive Hepatocellular
Carcinoma
1/2 60 CAR-T Cell Immunotherapy for HCC
Targeting GPC3
GPC3 NCT02723942 Completed
Carcinoma, Hepatocellular 1/2 30* A Study of GPC3 Redirected Autologous T
Cells for Advanced HCC (GPC3-CART)
GPC3 NCT02715362 Recruiting
Advanced Lung Cancer 1 22* CAR-T Cell Immunotherapy for Advanced
Lung Cancer
PD-L1 NCT03330834 Not Yet Open
Advanced Solid Tumor 1/2 40* CTLA-4 and PD-1 Antibodies Expressing
MUC1-CAR-T Cells for MUC1 Positive
Advanced Solid Tumor
MUC1 NCT03179007 Recruiting
Colon Cancer, Esophageal
Carcinoma, Pancreatic Cancer,
Prostate Cancer, Gastric Cancer,
Hepatic Carcinoma
1/2 60* A Clinical Research of CAR T Cells
Targeting EpCAM Positive Cancer
(CARTEPC)
EpCAM NCT03013712 Recruiting
Pancreatic Cancer 1 30* A Study of Mesothelin Redirected
Autologous T Cells for Advanced
Pancreatic Carcinoma (meso-CART)
Mesothelin NCT02706782 Recruiting
Lung Cancer 1 30* PSCA/MUC1/PD-L1/CD80/86-CAR-T
Cells Immunotherapy Against Cancers
PSCA, MUC1,
PD-L1 or CD80/86
NCT03198052 Recruiting
Sarcoma, Osteoid Sarcoma,
Ewing Sarcoma
1/2 20* Safety and Efficacy Evaluation of 4th
Generation Safety-engineered CAR T Cells
Targeting Sarcomas
Sarcoma-specific
CAR-T cells
NCT03356782 Recruiting
Lung Cancer 1/2 20* Intervention of CAR-T Against Lung
Cancer
Lung
cancer-specific
CAR-T cells
NCT03356808 Not Yet Open
Breast Cancer, Ovarian Cancer,
Lung Cancer, Gastric Cancer,
Colorectal Cancer, Glioma,
Pancreatic Cancer
1/2 60* A Clinical Research of CAR T Cells
Targeting HER2 Positive Cancer
HER2 NCT02713984 Recruiting
Cervical Cancer 1/2 20* Intervention of CAR-T Against Cervical
Cancer
Cervical
cancer-specific
CAR-T cells
NCT03356795 Recruiting
Hepatocellular Carcinoma,
Squamous Cell Lung Cancer
1 30* GPC3-T2-CAR-T Cells for Immunotherapy
of Cancer With GPC3 Expression
GPC3 NCT03198546 Recruiting
Liver Metastases 1/2 20* A Study of MG7 Redirected Autologous T
Cells for Advanced MG7 Positive Liver
Metastases(MG7-CART)
MG7 NCT02862704 Recruiting
EGFR-positive Colorectal Cancer 1/2 20* EGFR CART Cells for Patients With
Metastatic Colorectal Cancer
EGFR NCT03152435 Recruiting
Advanced Solid Tumor 1/2 40* CTLA-4 and PD-1 Antibodies Expressing
EGFR-CAR-T Cells for EGFR Positive
Advanced Solid Tumor
EGFR NCT03182816 Recruiting
Liver Neoplasms 2 25* Study Evaluating the Efficacy and Safety
With CAR-T for Liver Cancer (EECLC)
EPCAM NCT02729493 Recruiting
Stomach Neoplasms 2 19* Study Evaluating the Efficacy and Safety
With CAR-T for Stomach Cancer (EECSC)
EPCAM NCT02725125 Recruiting
Liver Metastases 1 5* CAR-T Hepatic Artery Infusions for
CEA-Expressing Liver Metastases
(HITM-SURE)
CEA NCT02850536 Recruiting
Carcinoma, Hepatocellular 1/2 10* A Study of GPC3-targeted T Cells by
Intratumor Injection for Advanced HCC
(GPC3-CART)
GPC3 NCT03130712 Recruiting
Liver Metastases 1 8 CAR-T Hepatic Artery Infusions and
Sir-Spheres for Liver Metastases
(HITM-SIR)
CEA NCT02416466 Ongoing, not
recruiting
Advanced EGFR-positive Solid
Tumors
1/2 60* Treatment of Chemotherapy Refractory
EGFR (Epidermal Growth Factor Receptor)
Positive Advanced Solid Tumors
(CART-EGFR) (CART-EGFR)
EGFR NCT01869166 Complete,
status
unknown
(Continued)
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TABLE 1 | Continued
Malignancy Phase N Name of Trial Therapeutic
Compounds
Clinical Trial
Identifier
Status
Hepatocellular Carcinoma, Liver
Cancer, Liver Neoplasms,
Metastatic Liver Cancer
1 18* Clinical Study of ET1402L1-CAR T Cells in
AFP Expressing Hepatocellular Carcinoma
ET1402L1 NCT03349255 Recruiting
Malignant Neoplasm of
Nasopharynx TNM Staging
Distant Metastasis (M), Breast
Cancer Recurrent
1 30* EpCAM CAR-T for Treatment of
Nasopharyngeal Carcinoma and Breast
Cancer
EpCAM NCT02915445 Recruiting
Mesothelin Positive Tumors 1 20* Anti-mesothelin CAR T Cells for Patients
With Recurrent or Metastatic Malignant
Tumors
Mesothelin NCT02930993 Recruiting
Hepatocellular Carcinoma 1 13 Anti-GPC3 CAR T for Treating Patients
With Advanced HCC
GPC3 NCT02395250 Terminated
Hepatocellular Carcinoma,
Non-small Cell Lung Cancer,
Pancreatic Carcinoma,
Triple-Negative Invasive Breast
Carcinoma
1/2 20* Phase I/II Study of Anti-Mucin1 (MUC1)
CAR T Cells for Patients With MUC1+
Advanced Refractory Solid Tumor
MUC1 NCT02587689 Recruiting
Pancreatic Cancer 1 4 Pilot Study of Autologous T-cells in
Patients With Metastatic Pancreatic
Cancer
Mesothelin NCT02465983 Completed
Advanced HER-2 Positive Solid
Tumors
1/2 10* Treatment of Chemotherapy Refractory
Human Epidermal growth Factor
Receptor-2(HER-2) Positive Advanced
Solid Tumors (CART-HER-2)
HER-2 NCT01935843 Recruiting
Lung Cancer, Colorectal Cancer,
Gastric Cancer, Breast Cancer,
Pancreatic Cancer
1 75* A Clinical Research of CAR T Cells
Targeting CEA Positive Cancer
CEA NCT02349724 Recruiting
Adult Advanced Cancer, Solid
Tumor
1/2 40* PD-1 Antibody Expressing CAR T Cells for
Mesothelin Positive Advanced
Malignancies
Mesothelin NCT03030001 Recruiting
Breast Cancer 1/2 60 Chimeric Antigen Receptor-Modified T
Cells for Breast Cancer
HER-2 NCT02547961 Completed
Pancreatic Cancer Early 1 10* Evaluate the Safety and Efficacy of CAR-T
in the Treatment of Pancreatic Cancer.
Mesothelin, PSCA,
CEA, HER2,
MUC1, EGFRvIII
NCT03267173 Recruiting
Prostate Cancer 1 18* CART-PSMA-TGFβRDN Cells for
Castrate-Resistant Prostate Cancer
PSMA, TGFβRDN NCT03089203 Recruiting
Carcinoma, Hepatocellular,
Pancreatic Cancer Metastatic,
Colorectal Cancer Metastatic
1/2 20* A Study of Chimeric Antigen Receptor T
Cells Combined With Interventional
Therapy in Advanced Liver Malignancy
GPC3, Mesothelin,
or CEA
NCT02959151 Recruiting
Advanced Solid Tumor 1/2 40* CTLA-4 and PD-1 Antibodies Expressing
Mesothelin-CAR-T Cells for Mesothelin
Positive Advanced Solid Tumor
Mesothelin NCT03182803 Recruiting
Metastatic Pancreatic (Ductal)
Adenocarcinoma, Epithelial
Ovarian Cancer, Malignant
Epithelial Pleural Mesothelioma
1 19 CART-meso in Mesothelin Expressing
Cancers
Mesothelin NCT02159716 Completed
Nasopharyngeal Neoplasms 1/2 20* A New EBV Related Technologies of T
Cells in Treating Malignant Tumors and
Clinical Application
LMP1 NCT02980315 Recruiting
Advanced Malignancies 1/2 20* PD-1 Antibody Expressing CAR-T Cells for
EGFR Family Member Positive Advanced
Solid Tumor
EGFR NCT02873390 Recruiting
Hepatocellular Carcinoma 1/2 20* Anti-GPC3 CAR-T for Treating
GPC3-positive Advanced Hepatocellular
Carcinoma (HCC)
GPC3 NCT03084380 Recruiting
Advanced Solid Tumor 1/2 20* PD-1 Antibody Expressing CAR-T Cells for
EGFR Family Member Positive Advanced
Solid Tumor (Lung, Liver and Stomach)
EGFR NCT02862028 Recruiting
(Continued)
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TABLE 1 | Continued
Malignancy Phase N Name of Trial Therapeutic
Compounds
Clinical Trial
Identifier
Status
Pancreatic Cancer 1 18* CAR T Cell Immunotherapy for Pancreatic
Cancer
Mesothelin NCT03323944 Recruiting
Lung Adenocarcinoma, Ovarian
Cancer, Peritoneal Carcinoma,
Fallopian Tube Cancer,
Mesotheliomas Pleural,
Mesothelioma Peritoneum
1 30* CAR T Cells in Mesothelin Expressing
Cancers
Mesothelin NCT03054298 Ongoing, not
recruiting
Bladder Cancer, Urothelial
Carcinoma Bladder
1/2 20* Intervention of Bladder Cancer by CAR-T PSMA and FRa NCT03185468 Recruiting
Malignant Mesothelioma,
Pancreatic Cancer, Ovarian
Tumor, Triple Negative Breast
Cancer, Endometrial Cancer,
Other Mesothelin Positive
Tumors
1 20* Treatment of Relapsed and/or
Chemotherapy Refractory Advanced
Malignancies by CART-meso
Mesothelin NCT02580747 Recruiting
Liver Cancer, Pancreatic Cancer,
Brain Tumor, Breast Cancer,
Ovarian Tumor, Colorectal
Cancer, Acute Myeloid and
Lymphoid Leukemias
1 20* Treatment of Relapsed and/or
Chemotherapy Refractory Advanced
Malignancies by CART133
CD133 NCT02541370 Recruiting
Lung Squamous Cell Carcinoma 1 20* Anti-GPC3 CAR T for Recurrent or
Refractory Lung Squamous Cell
Carcinoma
GPC3 NCT02876978 Recruiting
Malignant Melanoma, Breast
Cancer
Early 1 10* Autologous T Cells Expressing MET scFv
CAR (RNA CART-cMET)
cMET NCT03060356 Recruiting
Sarcoma, Osteosarcoma,
Neuroblastoma, Melanoma
1 15 A Phase I Trial of T Cells Expressing an
Anti-GD2 Chimeric Antigen Receptor in
Children and Young Adults With GD2+
Solid Tumors
GD2 NCT02107963 Completed
Non-Resectable Pancreatic
Cancer
1 30* Prostate Stem Cell Antigen
(PSCA)-Specific CAR T Cells In Subjects
With Non-Resectable Pancreatic Cancer
PSCA NCT02744287 Recruiting
Hepatocellular Carcinoma 1 14* Glypican 3-specific Chimeric Antigen
Receptor Expressing T Cells for
Hepatocellular Carcinoma (GLYCAR)
(GLYCAR)
Glypican 3 NCT02905188 Recruiting
Metastatic Cancer, Metastatic
Melanoma, Renal Cancer
1/2 24 CAR T Cell Receptor Immunotherapy
Targeting VEGFR2 for Patients With
Metastatic Cancer
VEGFR2 NCT01218867 Completed
Cervical Cancer, Pancreatic
Cancer, Ovarian Cancer,
Mesothelioma, Lung Cancer
1/2 136* CAR T Cell Receptor Immunotherapy
Targeting Mesothelin for Patients With
Metastatic Cancer
Mesothelin NCT01583686 Recruiting
Solid Tumor 1/2 100* Study on GD2 Positive Solid Tumors by
4SCAR-GD2
GD2 NCT02992210 Recruiting
Colon Cancer Liver Metastasis 1 18* Hepatic Transarterial Administrations of
NKR-2 in Patients With Unresectable Liver
Metastases From Colorectal Cancer (LINK)
NKR-2 NCT03370198 Recruiting
Metastatic Breast Cancer, Triple
Negative Breast Cancer
1 15* cMet CAR RNA T Cells Targeting Breast
Cancer
cMet RNA NCT01837602 Ongoing, not
recruiting
Colorectal Cancer, Ovarian
Cancer, Urothelial Carcinoma,
Triple-negative Breast Cancer,
Pancreatic Cancer
1 24* A Dose Escalation Phase I Study to
Assess the Safety and Clinical Activity of
Multiple Cancer Indications (THINK)
NKR-2 NCT03018405 Recruiting
Stage IV Breast Cancer, Stage IV
Non-Small Cell Lung Cancer,
Triple-Negative Breast
Carcinoma
1 60* Genetically Modified T-Cell Therapy in
Treating Patients With Advanced ROR1+
Malignancies
ROR1 NCT02706392 Recruiting
(Continued)
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TABLE 1 | Continued
Malignancy Phase N Name of Trial Therapeutic
Compounds
Clinical Trial
Identifier
Status
Hepatocellular Carcinoma 20* CAR-GPC3T Cells in Patients With
Refractory Hepatocellular Carcinoma
GPC3 NCT03146234 Recruiting
Sarcomas 1 26* iC9-GD2-CAR-VZV-CTLs/Refractory or
Metastatic GD2-positive Sarcoma/VEGAS
GD2 NCT01953900 Ongoing, not
recruiting
Pancreatic Cancer, Renal Cell
Cancer, Breast Cancer,
Melanoma, Ovarian Cancer
1/2 113* Administering Peripheral Blood
Lymphocytes Transduced With a
CD70-Binding Chimeric Antigen Receptor
to People With CD70 Expressing Cancers
hCD70 NCT02830724 Recruiting
Breast Cancer, Metastatic
HER2-negative Breast Cancer
1 24* T-Cell Therapy for Advanced Breast
Cancer
Mesothelin NCT02792114 Recruiting
*Means estimated sample size.
TABLE 2 | List of antigens targeted by CART in pre-clinical glioma model.
Antigen Generation Other Treatments/Modifications Reference
NKG2D Second Generation Radiotherapy/ NKG2D–CD3ζ-DAP10 Weiss et al. (49)
GD2 Third Generation Engineered with active IL-7 receptor (C7R) and a 41BB.ζ
signaling endodomain
Shum et al. (50)
IL13Rα2 Second Generation Engineered contain either a CD28.ζ, 41BB.ζ CD28.OX40.ζ, or
CD28.41BB.ζ endodomain
Krenciute et al. (51)
EGFRvIII Third Generation Engineered to express miR-17-92 with CD28, 41BB and
CD3ζ signaling
Ohno et al. (52)
EGFRvIII Third Generation Engineered to contain a CD28-41BB-CD3ζ endodomain Choi et al. (53)
EGFRvIII Second Generation Engineered with ICOS and CD3ζ signaling domain Shen et al. (54)
NY-ESO-1 N/A Decitabine, in culture/ modified CDR Everson et al. (55)
EGFRvIII Third Generation Engineered with mouse CD8 trans-membrane and mouse
CD28, 4-1BB, and CD3ζ intracellular regions
Sampson et al. (56)
the context of MHC molecules and therefore not accessible
to traditional CARs. Due to a lack of known feasible tumor-
exclusive antigens, many TAAs under current evaluation
for CART immunotherapy are derived from overexpressed
endogenous molecules, particularly those that promote tumor
proliferation and persistence (i.e., growth factor receptors).
Their disproportionately high degree of upregulation within
tumors allows for preferential targeting of malignant cells.
However, there are several important challenges and health
risks associated with targeting overexpressed self-antigens
that must be considered. Due to the natural development
of tolerance to endogenous peptides, the majority of these
overexpressed TAAs are poorly immunogenic. However,
enhancing CART cytotoxicity against epitopes not restricted
to malignant cells is limited by the danger of simultaneously
promoting CAR recognition of target antigen expressed by
healthy tissues. Toxicities secondary to unintentional destruction
of non-cancerous cells has been observed to varying degrees
following CART therapy targeting overexpressed self-antigens
like CEA, a tumor-associated antigen that is also expressed in
normal gastrointestinal epithelium. In a study of CEA-targeting
CART immunotherapy for metastatic colorectal cancer, tumor
regression was accompanied by severe inflammatory colitis in all
treated patients, due to the destruction of healthy epithelial cells
(59). Depending on the location of off-target antigen expression,
the resulting toxicities may have life-threatening consequences,
as occurred in a patient receiving CART therapy for refractory
HER2-overexpressing metastatic colorectal cancer. This patient
experienced fatal pulmonary toxicity shortly after CART infusion
secondary to CAR recognition of low levels of HER2 on lung
epithelium (60).
Identification of a tumor-exclusive antigen target feasible
for CART immunotherapy is further complicated by the often
inconsistent and incomplete degree of expression of unique
tumor epitopes throughout the tissue. As a result, there likely
exists a subpopulation of malignant cells lacking expression of
any given target antigen that will therefore evade destruction
by a corresponding CAR T-cell. In addition to reducing overall
therapeutic efficacy this creates a selective pressure for the
accumulation of cells with absent or mutated target antigen
expression, introducing the potential for tumor recurrence
through expansion of antigen-negative cell populations. This
is particularly applicable when targeting epitopes derived from
mutations that are not crucial to oncogenesis and tumor
survival, as these structures can be readily modified or lost
without compromising vital tumor functions. Indeed, therapy
resistance coinciding with the emergence of antigen-loss variants
is commonly observed in human patients with GBM and other
solid tumors following treatment with CART immunotherapy
(43, 45, 46, 61, 62).
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TABLE 3 | List of CART immunotherapy clinical trials in malignant gliomas.
Malignancy Phase N Name of Trial Target Clinical Trial
Identifier
Status
Advanced Glioma 1 10* CAR T Cells in Treating Patients With Malignant
Gliomas Overexpressing EGFR
EGFR NCT02331693 Completed,
Unknown
GD2 Positive Glioma 1/2 60 CAR-T Cell Immunotherapy for GD2 Positive Glioma
Patients
GD2 NCT03252171 Completed
EphA2 Positive Malignant Glioma 1/2 60 CAR-T Cell Immunotherapy for EphA2 Positive
Malignant Glioma Patients
EphA2 NCT02575261 Completed
Glioblastoma 1/2 107* CAR T Cell Receptor Immunotherapy Targeting
EGFRvIII for Patients With Malignant Gliomas
Expressing EGFRvIII
EGFRvIII NCT01454596 Recruiting
Malignant Glioma, Colorectal
Carcinoma, Gastric Carcinoma
1/2 20* CAR-T Cell Immunotherapy in MUC1 Positive Solid
Tumor
MUC1 NCT02617134 Recruiting
Residual or Recurrent EGFRvIII+
Glioma
1 12* Autologous T Cells Redirected to EGFRVIII-With a
Chimeric Antigen Receptor in Patients With
EGFRVIII+ Glioblastoma
EGFRvIII NCT02209376 Ongoing, Not
recruiting
Malignant Glioma, Refractory Brain
Neoplasm, Recurrent Brain Neoplasm
1 135* Genetically Modified T-cells in Treating Patients With
Recurrent or Refractory Malignant Glioma
IL13Rα2 NCT02208362 Recruiting
Malignant Glioma, other advance
solid tumors
1/2 10* CAR-pNK Cell Immunotherapy in MUC1 Positive
Relapsed or Refractory Solid Tumor
MUC1 NCT02839954 Recruiting
Glioma, other advance solid tumors 1/2 60* A Clinical Research of CAR T Cells Targeting HER2
Positive Cancer
HER2 NCT02713984 Recruiting
Recurrent Glioblastoma 1 24* Intracerebral EGFR-vIII CAR-T Cells for Recurrent
GBM (INTERCEPT)
EGFRvIII NCT03283631 Not yet open
Glioblastoma 1 48* EGFRvIII CAR T Cells for Newly-Diagnosed GBM
(ExCeL)
EGFRvIII NCT02664363 Recruiting
Glioblastoma 1 20* Pilot Study of Autologous Anti-EGFRvIII CAR T Cells
in Recurrent Glioblastoma Multiforme
EGFRvIII NCT02844062 Recruiting
Glioblastoma 1 16 CMV-specific Cytotoxic T Lymphocytes Expressing
CAR Targeting HER2 in Patients With GBM
(HERT-GBM)
HER2 NCT01109095 Ongoing, Not
recruiting
Glioblastoma 1/2 20* 4SCAR-IgT Against Glioblastoma Multiform EGFRvIII NCT03170141 Open,
invitation only
Glioblastoma 1 14* T Cells Expressing HER2-specific Chimeric Antigen
Receptors (CAR) for Patients With Glioblastoma
(iCAR)
HER2 NCT02442297 Recruiting
Glioblastoma 1 20* Pilot Study of Autologous Chimeric Switch Receptor
Modified T Cells in Recurrent Glioblastoma
Multiforme
PD-L1 NCT02937844 Recruiting
*Means estimated sample size.
Lymphocyte Trafficking
In contrast to the simplicity and ease of encountering of
malignant cells in hematologic cancers, CARTs for solid tumors
face the additional challenge of migrating to and infiltrating
tumor sites. In humans and mice, CART persistence and
intratumoral accumulation following systemic adoptive transfer
is characteristically poor (63), with some studies showing
initial trafficking to organs such as the lung, spleen, and liver,
without any preferential accumulation in tumor sites (64).
This limited trafficking may be multifactorial and impacted
by both lymphocyte and tumor related influences, including
settings of mismatch between tumor-expressed molecules and
corresponding lymphocyte receptors (65) and the development
of structural barriers surrounding tumor sites (66). With a
reduced capacity to proliferate and relatively short overall
persistence, CART immunotherapy in solid tumors becomes a
“race against the clock,” as adoptively transferred cells have a
limited amount of time to reach and destroy malignant cells,
including those at sites distant to the bulk tumor.
Normal leukocyte migration and extravasation from the
bloodstream is a multistep process that can be separated into
four characteristic stages: (1) tethering/rolling, (2) activation, (3)
adhesion/arrest, and (4) transmigration. Transient interactions
between leukocyte carbohydrates and endothelial cell selectin
receptors slows leukocyte velocity, causing them to roll along the
endothelial wall in the direction of blood flow. These tethering
interactions bring leukocytes in closer proximity to chemokines
secreted by vascular endothelium, which bind leukocyte G-
protein coupled receptors that activate the expression and
adhesiveness of surface integrins, including lymphocyte function
antigen-1 (LFA-1) and very late antigen (VLA)-4. Binding of
these integrins to their ligands, like VCAM-1 and ICAM-1,
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FIGURE 4 | Barriers to successful CART immunotherapy in solid tumors. (A) Factors within the tumor microenvironment: Solid tumors contain an abundance of
immunosuppressive leukocytes, immune checkpoint molecules, and suppressive cytokines. The tumor cells themselves are highly heterogeneous, preventing the
identification of uniformly expressed targets for CAR design; antigen selection is further limited by an inability of CARTs to target intracellularly derived antigens.
(B) Barriers to CART migration and entry into tumor sites: In contrast to the disseminated nature of hematologic cancers, solid tumors are often found in isolated
locations that are difficult to access, like the brain. (a) following adoptive cancer, CARTs have been shown to preferentially accumulate in organs such as the lungs,
liver, and spleen, with limited natural trafficking to tumor sites. (b) downregulated expression of ICAMs and other adhesion molecules on tumor vasculature limits
lymphocyte extravasation, (c) reduced release of lymphocyte-attracting chemokines such as CXCL9-11 precludes CART homing to tumor sites, (d) in addition to
supporting the growth and persistence of malignant cells, tumor-associated stroma provides both a physical and immunologic barrier to CART immunotherapy, (e)
release of angiogenic factors such as VEGF promotes the develop of abnormal, tortuous, high-pressure vasculature that impedes lymphocyte entry.(C) Toxicity
secondary to off-target effects: the use of overexpressed self-antigens as CAR targets introduces the risk of significant toxicity associated with CART identification and
destruction of normal, healthy cells expressing these antigens.
present on tumor vasculature leads to a firm arrest of leukocyte
motion. This stronger binding provides for transmigration into
tumor sites (67).
In the setting of cancer, preferential migration of immune cells
to tumor sites is mediated by tumor-secreted chemoattractants
such as CCL2, CXCL9, CXCL10, and CXCL11 (65). An
expression of corresponding receptors allows activated T-
cells to respond to these factors, inducing migration in
the direction of increasing chemokine concentration. This
relationship between tumor-expressed chemoattractants and the
profile of corresponding T-cell homing receptors is crucial
in dictating a leukocyte’s capacity to traffic to tumor sites
(68). In a study of CTL trafficking in murine brain tumors,
Okada et al. observed that CNS homing capacity was restricted
to CTLs polarized toward a type 1, as compared to type
2, cytokine profile, demonstrating the importance of tumor
tropism. These type 1 CTLs exhibited comparatively higher levels
of endogenous VLA-4 and CXCR3, receptors that are crucial
for CNS tropism (2). GBM and other highly vascular tumors
characteristically overproduce vascular endothelial growth factor
(VEGF), which, in addition to promoting angiogenesis, inhibits
the secretion of lymphocyte-attracting chemokines like CXCL10
and CXCL11 (69) and downregulates tumor endothelial cell
expression of adhesion molecules like ICAM-1 and ICAM-2,
VCAM-1 and CD34 (70). Also abundant within the TME is the
immunosuppressive cytokine TGF-β, which also downregulates
endothelial cell expression of cellular adhesion molecules,
thereby inhibiting T-cell transmigration (17).
Solid tumors also induce the development of structural
modifications to the adjacent tissue that can prevent intratumoral
lymphocyte accumulation. Many solid tumors are surrounded
by a dense, peritumoral fibrous stroma that insulates nests of
tumor cells from the surrounding environment (66). Forming
the structural framework of this stroma are cancer-associated
fibroblasts (CAFs), which play an important role in regulating
tumor metabolism, growth, and persistence and mediate tumor
invasion and metastasis through remodeling of the extracellular
matrix (70, 71). Endogenous T-cells express heparanase, an ECM-
degrading enzyme, which enhances their ability to penetrate this
stroma; however, heparanase expression is often lost during in
vitro culture, preventing CART from entering tumor sites (71).
Abundantly secreted by tumor and stromal cells are CXCL-
12, VEGF, and PDGF, which recruit bone marrow-derived
endothelial cells and promote the development of abnormal,
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tortuous vessels leading to the development of abnormal, leaky
vascular networks and elevated intratumoral interstitial pressures
that resist lymphocyte infiltration (66).
Tumor-Induced Immunosuppression
A major barrier to the efficacy of CART immunotherapy
in solid tumors is a characteristic state of profound tumor-
induced suppression of host antitumor immunity (72–74). The
complex network of signals orchestrated by malignant and
non-malignant cells of a tumor induces the development of
an environment that is hostile to immune cell function and
survival and favors tumor persistence. Through the elaboration
of immunosuppressive cytokines and other soluble mediators,
recruitment of inhibitory leukocytes, and activation of immune
checkpoints, tumors create a microenvironment that inhibits
effector cell activity and resists immune-mediated destruction.
This multitude of immunosuppressive influences is responsible
for the rapid loss of effector function observed upon CART entry
into tumor sites (75).
Through surface expression of immunosuppressive
molecules, solid tumors exploit endogenous regulatory pathways
to directly inhibit T-cell effector functions. Among these
immune checkpoints are the programmed cell death-1 (PD-1)
and cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathways.
Activation of CTLA-4 receptors expressed by naïve T cells
prevents their initial activation and stimulation of PD-1 on
activated T-cells induces anergy, apoptosis, or development of
immunosuppressive regulatory T-cells (Tregs). By upregulating
PD-L1 and enhancing T-cell CTLA-4 and PD-1 expression,
tumor cells are able to suppress the activity of incoming immune
cells (76).
Present in high concentrations within the glioma
microenvironment are immunoregulatory cytokines like
transforming growth factor-β (TGF-β) and interleukin 10
(IL-10), which support the development of a type-2 polarized
environment. In addition to suppressing MHC II molecule
expression and antigen presenting cell maturation and function,
these cytokines are potent inhibitors of T-cell differentiation,
proliferation, and cytotoxicity (77, 78). Accumulating within
gliomas and other solid tumors are inhibitory leukocytes like
regulatory T-cells, myeloid-derived suppressor cells (MDSCs),
and tumor-associated macrophages (TAMs), which are potent
inhibitors of antitumor immunity (66). MDSCs constitute a
diverse pool of immature myeloid cells that accumulate in
settings of inflammation and malignancy. Through cell-cell
contacts and the release of soluble mediators, MDSCs suppress
the proliferation and function of antigen-specific CTLs and
induce the development of Treg cells (79).
OVERCOMING CHALLENGES AND
FUTURE DIRECTIONS
Although the application of CART immunotherapy to solid
tumors continues to be faced with significant challenges, this
therapeutic modality still holds the potential to make a significant
impact in the field of solid tumors as it did for liquid
malignancies.
Antigen Selection
Moving forward, the identification of commonly expressed
antigen targets remains a constant challenge plaguing CART
development for solid tumors. However, given the high degree
of solid tumor heterogeneity existing across different patients,
identification of such a broadly applicable antigen has been
problematic. Despite the challenges facing antigen selection
in solid tumors, CARs developed against a variety of TAAs
have demonstrated encouraging antitumor efficacy and safety
profiles in preliminary studies. One potential solution involves
the study of individual intratumoral mutation profiles, which
has revealed an exciting new category of possible antigen
targets that may allow for the development of highly specific
and effective personalized therapies (80, 81). Arising through
somatic mutations within an individual tumor, these “neo-
antigens” are inherently both tumor-specific and immunogenic.
Endogenous T-cells naturally activated against these unique,
patient-specific epitopes have been recovered from the tumors
and peripheral blood of patients with a variety of solid
cancers (82–84). Interestingly, patients with higher numbers
of these immunogenic neo-antigens have been shown to
possess a greater expansion of antigen-reactive CD8+ T-
cells and elevated immune checkpoint expression, which may
suggest synergy between CART immunotherapy and immune
checkpoint blockade (85). Furthermore, the generation of
these novel epitopes can be enhanced with other forms
of immunotherapy known to trigger epitope spreading and
activate antitumor immune responses, like dendritic cell-based
vaccination or oncolytic virotherapy (86, 87). Aiding in the
development of neo-antigen-based therapies, tumor exome and
proteome analysis allows for a characterization of the full profile
of neo-antigens within a single tumor and identification of
epitopes that may be particularly immunogenic (88–90). Using
this information, Castle et al. demonstrated the ability to induce
T-cell immune responses against patient-specific neo-antigens
via peptide vaccination against immunogenic epitopes (91).
Given that the majority of these novel epitopes created within
solid tumors are peptide-based antigens, CARTs have been
developed in which the CAR ectodomain consists of a TCR-like
construct that recognizes MHC-presented intracellular antigens
(92). Indeed, transfection of T-cells with neo-antigen-specific
receptors has been shown to be a viable option in preclinical
studies (93, 94).
Targeting multiple TAAs has potential to enhance overall
specificity for tumor cells, lessen the risk of off-target effects,
and reduce the emergence of antigen loss variants and therapy-
resistant tumors. After studying single-cell coexpression patterns
of the TAAs HER2, IL-13Rα2, and EphA2 in primary GBM
samples, Hegde et al. developed a mathematical model of antigen
expression to predict the odds of complete tumor elimination
with CART therapy. This model determined that a maximal
expansion of CART therapeutic potential in all tumors can
be achieved by co-targeting HER2 and IL-13Rα2, without any
added advantage to targeting a third antigen. They subsequently
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developed bi-specific HER2 and IL-13Rα2-targeting CAR T-cells
that exhibited enhanced antitumor activity and an ability to
offset antigen escape in in vitro immunoassays and an orthotopic
xenogeneic murine model (95). Tumor cell selectivity of bi-
specific CAR T-cells can be further refined to only target cells
expressing a specific antigen combination. This is achieved
by physically separating CAR signaling domains between two
distinct CARs specific for two different antigens, such that
binding of both CARs to their individual target antigens is
required to transmit an activating signal to induce T-cell
cytotoxicity (96). This technique may be particularly effective
against tumors that overexpress two antigens that are individually
not exclusively expressed by malignant cells, but when coupled
together, result in acceptable tumor specificity due to a lack of
overlapping expression on non-target tissues.
Considering tumor-associated stroma is also important for
therapy development. For example, in tumors with a high
degree of antigen expression, CART immunotherapy has been
shown to indirectly eradicate antigen loss variants, a process
dependent on tumor stromal cell cross-presentation of TAAs
(97). Further studies demonstrated that in settings of low antigen
expression, local irradiation or chemotherapy was shown to
cause sufficient release of antigen to sensitize stromal cells for
T-cell mediated destruction, supporting introduction of CART
immunotherapy into standard treatment regiments including
radio and chemotherapy (98). Directly targeting antigens present
on tumor-supporting structures such as tumor vasculature or
associated stroma is also a promising option. CARTs directed
against antigens preferentially expressed by tumor vasculature
have been shown to directly disrupt these vascular networks
leading to tumor regression in murine models of ovarian cancer
and other vascular tumors (99). CARTs targeting fibroblast
activation protein-α (FAP), a tumor stromal-associated antigen
expressed by CAFs, delivered in combination with an EphA2-
targeting CAR population was shown to control the tumor
growth in an A549 lung cancer model more effectively than either
agent alone (37).
Lymphocyte Trafficking
A variety of methods have been successfully employed to enhance
CART trafficking to tumor sites including augmenting CART
responsiveness to tumor-secreted cytokines, targeting tumor-
associated stroma and the TME, and exploration of regional
routes of delivery.
Fundamentally, T-cell migration and intratumoral
accumulation will be facilitated by the utilization of T-cell
populations expressing a profile of homing receptors allowing
them to respond to the unique factors secreted by an individual
tumor. To overcome tumor chemokine and lymphocyte
receptor mismatches, CAR T-cells can be transduced with
specific chemokine receptors known to dictate the appropriate
tissue tropism (100, 101). For example, transfection of CARTs
with a gene for CCRb2, the chemokine receptor for the T-cell
chemoattractant CCL2, has been shown to enhance themigration
and intratumoral accumulation of CARTs in xenograft models
of multiple solid tumor types (33, 102). Brown et al. reported
that glioma-derived CCL2/MCP-1 is ultimately responsible
for the in vivo chemotaxis of adoptively transferred T-cells to
glioma xenograft tumor sites (103), introducing promise for
similar studies in glioma. CAR T-cells have been engineered to
express heparanase, a modification that enhances intratumoral
accumulation and overall antitumor activity (71). Combining
multiple immunotherapeutic strategies to improve trafficking,
one study evaluated CARTs delivered together with an oncolytic
adenovirus engineered to express both a chemokine and T-cell
growth factor. The combination of RANTES and IL-15 was
shown to improve T-cell trafficking to tumor sites as well as
create a favorable environment within the TME to enhance
immune cell persistence (104).
In theory, any therapy that favorably modulates the TME or
enhances the elaboration of relevant chemokines will enhance
the migration of CARTs to tumor sites. In addition to
mollifying the tumor-induced suppression of T-cell activity,
immune checkpoint blockade with anti-PD-1 therapy augments
lymphocyte trafficking in tumor-bearing mice by promoting the
elaboration of the lymphocyte-attracting cytokines interferon-
γ (IFN-γ) and CXCL10 (105). Similar effects are achieved
with radiotherapy, which leads to IFN-γ-enhanced expression
of adhesion molecules on tumor-associated vasculature (106).
Anti-angiogenic therapy also promotes lymphocyte infiltration
into tumor sites, and administration in combination with CART
immunotherapy has been shown to be more therapeutically
effective than treatment with either modality alone (107, 108).
In addition to normalization of tumor vasculature, inhibition of
VEGF signaling in a B16 melanoma model resulted in an 18-fold
increase in intratumoral T-cell infiltration, which was associated
with increased expression of CXCL10 and CXCL11 (69).
Proposed to circumnavigate many of the barriers limiting
the trafficking of systemically delivered CARTs, regional CART
administration may be a superior delivery strategy for CARTs in
solid tumors. In contrast to the need for systemically delivered
cells to traffic to tumor sites, intratumorally delivered cells have
been shown largely to remain at the site of inoculation with
minimal systemic absorption, which suggests that regionally
delivered CARTsmay carry a lower risk of off-target toxicities (63,
109). Several additional studies evaluating the efficacy of systemic
and regionally delivered CART therapy have found regional
delivery methods to result in superior T-cell persistence and
overall therapeutic efficacy (32, 110). In one such comparison,
regional intra-pleural delivery of mesothelin-targeting CAR T-
cells resulted in earlier intratumoral accumulation, increased
CD8+ T-cell proliferation and persistence, enhanced cytokine
secretion, and improved overall therapeutic efficacy in an
orthotopic model of human pleural malignancy. Adoptively
transferred cells exhibited long-term persistence and protection
against tumor rechallenge after 200 days (110). The application of
such a regional delivery method may be especially advantageous
in the setting of poorly accessible intracranial tumors like
GBM that, nestled within a strongly immunosuppressive
microenvironment, are significantly isolated from the systemic
circulation. With respect to intracranial tumors, an in vivo study
of breast cancer xenograft tumors with intracranial metastases
was conducted to compare two regional CART delivery methods:
intraventricular and a more localized, intracranial method. With
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both methods, functionally active, antigen-specific CD4+ and
CD8+ T-cells were detected at tumor sites 1 week following
administration. In this study, CARTs were rarely detectable
by two weeks following administration Although equivalent
antitumor activity was observed, some mice receiving the
less localized intraventricular therapy exhibited more delayed
therapeutic responses, demonstrating the need for adoptively
transferred cells to traffic from the site of delivery (ventricle)
to tumor sites (111). This delayed onset of action associated
with T-cell trafficking makes the persistence of adoptively
transferred cells of utmost importance. Specific to glioma model,
intracerebral delivery of EGFRvIII-targeting CARTs has been
shown to induce tumor regression in murine models of glioma
(53). Several human clinical trials have employed regional CART
delivery methods for the treatment of patients with progressive
GBM. In one such phase I human clinical trial, following surgical
tumor debulking, IL13Rα2-targeted CARTs were infused into
the resection cavity via a Rickham catheter. Although this study
did not assess the duration of CART persistence within the
target tissue or at other locations, it proved that this route of
administration was well tolerated and established feasibility for
future evaluations (45). More recently, Brown et al. reported
observations regarding two different regional CART delivery
routes employed in the treatment of one patient with multifocal
GBM. Transient anti-glioma responses were seen following
initial intracranial CART delivery. After tumor recurrence, the
patient was treated with intraventricular CART infusions and
experienced robust tumor regression over the course of 7.5
months, though eventually succumbing to multifocal relapsed
disease. Investigators evaluated CART persistence and cytokine
levels in relation to intraventricular infusions. CAR T-cells were
detected within the CSF for up to 1 week following infusion,
with peak concentrations occurring after 2 days. Despite this
lack of robust persistence, there was a significant induction of
inflammatory cytokines, including IFN-γ, TNF-α, IL-12, IL-5,
IL-6, IL-8, IL-10, CXCL9, CXCL10, CCR2, and IL-1Rα (46).
Further studies will be needed to characterize and contrast the
T-cell persistence and overall therapeutic efficacy associated with
regional and systemically delivered CART therapies in the setting
of GBM.
CART Cell Persistence
The persistence of adoptively transferred T-cells is directly
correlated with patient clinical responses and the degree of tumor
regression (112). Although factors impacting CART persistence
remain poorly understood, there have been several key advances
in this field that have shown promise for optimizing persistence
and associated therapeutic efficacy.
The selection of different costimulatory motifs can confer
unique properties in terms of cellular metabolism, cytokine
secretion, cytotoxicity, proliferation, persistence, and memory
cell generation. Costimulation with 4-1BB derived moieties
promotes the generation of long-lived central memory cells with
enhanced mitochondrial biogenesis and fatty acid oxidation.
Signaling through a different pathway, CD28 leads to the
differentiation of shorter-lived effector memory cells and
metabolic changes leading to increased reliance on aerobic
glycolysis for proliferative energy (113). A diverse combination
of different subpopulations of CARTs possessing the unique
strengths and weaknesses of differential costimulation may
provide the most effective overall antitumor effect.
In addition to structural CAR modifications, CART
persistence is classically enhanced by pretreatment
lymphodepletion with cyclophosphamide or fludarabine
(114). Lymphodepletion is thought to support T-cell engraftment
by depleting populations of suppressive host lymphocytes, like
Tregs, and eliminating competition for cytokines like IL-7, IL-15,
and IL-21, which promote T-cell activation and expansion (115).
This effect can be further augmented with the administration
of supportive cytokines (116). The most widely studied is IL-2,
however in addition to supporting CTL persistence and function,
IL-2 also promotes the expansion of immunosuppressive
regulatory T-cells (117). In contrast, IL-15 has been shown to
preferentially promote cytotoxic T-cell persistence and function
even in the presence of Tregs (118). Persistence and cytotoxicity
are also influenced by the composition of the transferred CART
lymphocyte population (119), with infusions containing higher
numbers of CD4+ and memory T-cells exhibiting longer overall
longevity (57).
Overcoming Tumor-Induced
Immunosuppression
The clinical success of CART immunotherapy depends upon the
ultimate ability of tumor-infiltrating CTLs to retain their ability
to identify and destroy malignant cells within this suppressive
microenvironment. The immunosuppressive effects of the TME
can be addressed through a variety of strategies that enhance the
effector functions of adoptively transferred cells and/or directly
counteract mechanisms of tumor-induced immunosuppression.
In addition to exogenous administration of adjunctive therapies,
CAR T-cells themselves can be genetically engineered to secrete
immune-modulating compounds or to reduce their susceptibility
to tumor-induced immunosuppression.
The success of CART immunotherapy can also be improved
by strategies that focus on altering the anti-inflammatory and
immunosuppressive nature of the TME by armoring them with
immune modulating cytokines. CARTs engineered to express IL-
12 upon antigen binding release this pro-inflammatory cytokine
into the surrounding milieu, which functions to promote an
environment favoring antitumor immunity. By counteracting
the immunosuppressive nature of the TME, IL-12 lessens the
recruitment and suppressive influences of immature dendritic
cells, TAMs, Tregs, and MDSCs, and recruits additional innate
immune cells that may be able to destroy tumor cells that
are not visible to CARs (120). IL-12-expressing CARTs also
exhibit improved antitumor efficacy and have been shown to
be intrinsically resistant to Treg-mediated immunosuppression
(121). Overall, delivery of pro-inflammatory cytokines like IL-
12 has been shown to counter the immunosuppressive nature
of the local microenvironment by promoting the polarization
T-cell responses toward the T helper-1 phenotype, enhancing
IFN-γ release, augmenting granzyme and perforin production,
suppressing angiogenesis, and reducing the population of
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infiltrating MDSCs (122, 123). Antibody-mediated therapy to
deplete suppressor cells, including MDSCs and Tregs, has also
been shown to further reduce tumor burden (32). Alternatively,
CARTs can be modified to resist immunosuppressive influences
within the TME. Present in high amounts within tumor sites,
TGF-β has a profound inhibitory influence on the activity
of immune effector cells. CTLs transfected with a dominant
negative TGF-β receptor are rendered insensitive to TGF-
β-mediated suppression and were shown to have enhanced
antitumor activity as compared to unmodified CTLs (124).
Engineering CAR T-cells to be resistant to the multitude of
immunosuppressive influences within the TME is a constant goal
in the development of more sophisticated therapies.
Given the complexity of immune interactions within solid
tumors and their importance in disease outcome, there
inherently exists significant synergistic potential in combination
treatment with CARTs and other forms of immunotherapy,
such as dendritic cell-based vaccination, oncolytic virotherapy,
and immune checkpoint blockade (87, 125). Supporting this
assertion, simultaneous PD pathway blockade has been shown
to improve the cytotoxic activity of adoptively transferred CAR
T-cells, reduce the presence of MDSCs, and enhance tumor
growth inhibition in murine models (126). Overall, in addition
to attracting CARTs to tumor sites, the resulting enhanced
secretion of IFN-γ and CXCL10 creates a pro-inflammatory
TME favoring the development of antitumor immunity (105).
Immune checkpoint blockade with anti-PD pathway antibodies
can be achieved either through the exogenous coadministration
or via CART secretion. Anti-PD-L1 antibodies secreted by
CARTs have been shown to induce an efficient, localized PD
blockade that promoted T-cell cytotoxicity, NK cell recruitment,
and tumor growth control in a murine model of colorectal
carcinoma (127). An alternative, potentially more efficacious,
strategy to blocking immune checkpoint signaling is exchanging
the inhibitory signal transmitted by checkpoint activation for a
stimulatory one. T-cells can also be engineered to express decoy
receptors containing an extracellular domain similar to CTLA-4
or PD-1 that transmits an activating signal. CARTs expressing a
PD-1-CD28 switch receptor were shown to be more resistant to
tumor-induced immunosuppression, and in a solid tumor mouse
model resulted in enhanced TIL infiltration and tumor regression
as compared to treatment with CART therapy or PD-1 blockade
alone (128).
CONCLUSION
In conclusion, CART therapy has significant unrealized potential
to revolutionize the treatment of solid tumors, as it has already
done for hematologic cancers. A better understanding of factors
leading to the success of CART immunotherapy in these liquid
cancers and an analysis of those limiting the applicability of
CART therapy to solid tumors will be necessary to move this
field forward. Strategies that address the unique aspects of
solid tumor biology like molecular heterogeneity, isolated tumor
location, and associated immunosuppressionmust be thoroughly
studied to extend the use of CART immunotherapy to these
tumors. Further studies involving optimization of ex vivo culture
conditions, genetic manipulation of CAR and CART structure,
and investigation of combination therapies are necessary to
provide a lasting solution.
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